Background: Statins are commonly used cholesterol-lowering drugs that have proapoptotic and antimetastatic activities that could affect cancer risk or progression. Results from previous epidemiologic studies of the association between statin use and cancer have been inconsistent. We investigated the association of statin use with total and advanced prostate cancer, the latter being the most important endpoint to prevent. Methods: We analyzed data from an ongoing prospective cohort study of 34 989 US male health professionals who were cancer free in 1990 and were followed to 2002. Participants reported their use of cholesterol-lowering drugs on biennial questionnaires. Prostate cancer diagnosis was confi rmed by medical record review. Multivariable-adjusted relative risks (RRs) were estimated from Cox proportional hazards regression models. Statistical tests were two-sided. Statins are commonly used cholesterol-lowering medications with documented effectiveness in the primary and secondary prevention of heart attack and stroke ( 1 ) . Among other activities, statins have proapoptotic and antimetastatic effects, which may make them relevant to cancer prevention or treatment ( 2 , 3 ) . Recently, a small clinic-based case -control study ( 4 ) , a large case -control study within a medical records database ( 5 ) , and a case -control study within a pharmacy database ( 6 ) each reported a 50% -65% reduced risk of prostate cancer in statin users compared with nonusers. However, other observational studies ( 7 -11 ) and clinical trials ( 12 ) have not confi rmed the inverse association
between statin use and risk of prostate cancer. Statin use has also been inversely associated with breast cancer ( 13 , 14 ) , colorectal cancer ( 15 ) , and all cancers combined ( 6 , 8 , 11 ) in some studies, but other epidemiologic studies ( 7 , 9 , 10 , 16 -19 ) and clinical trials ( 12 , 20 ) have not provided evidence for an inverse association.
Given that statin drugs alter biologic pathways that may infl uence carcinogenesis and metastasis, and given the contradictory results in the literature, we examined their use in relation to both total prostate cancer and the more clinically important advanced prostate cancer in a large prospective cohort study of American men during the period when statin drugs have been widely prescribed in the United States. This cohort, the Health Professionals Follow-up Study, has served as the study population for investigations of risk factors for a number of different cancers, including prostate cancer. Prostate cancer is the fi rst cancer for which we have investigated the association for statins.
S UBJECTS AND M ETHODS

Study Population
Participants were members of the Health Professionals Follow-up Study, an ongoing prospective cohort study of diet and other risk factors for heart disease, cancer, and other conditions ( http://www.hsph.harvard.edu/hpfs/ ). In 1986, 51 529 men aged 40 -75 years enrolled by responding to a baseline questionnaire, which constituted consent. The men completed biennial mailed questionnaires on demographic factors, medical history, and lifestyle factors and every 4 years completed mailed semiquantitative food-frequency questionnaires. Deaths were reported by family members and the postal system or were identifi ed through the National Death Index, with a sensitivity of more than 98% ( 21 ) . The overall response rate to the biennial mailed questionnaires was 94%.
To encompass the era of statin drug use, we began follow-up on February 1, 1990 . We excluded men who returned an incomplete or invalid food-frequency questionnaire in 1990 (3.1%), men who had died (2.0%) or who had a cancer diagnosis (except for nonmelanoma skin cancer) (5.0%) before the start of follow-up, men who withdrew from the study (0.1%), and men who did not respond to the 1990 questionnaire or did not answer the section on medication use (22.0%), leaving 34 989 men. Men who did and did not provide information on medication use in 1990 were not systematically different with respect to mean age (58.0 years, standard deviation [SD] = 9.6 years, versus 57.1 years, SD = 9.5 years), the prevalence of having had routine screening for elevated prostate-specifi c antigen (PSA) by 2000 (92.0% and 88.8%, respectively, of those who responded to at least one questionnaire from 1994 and 2000), the prevalence of a history of elevated cholesterol at baseline in 1990 (31.8% and 27.7%, respectively), or the prevalence of use of statin drugs in 2000 (27.5% and 26.6%, respectively, of those who answered the 2000 questionnaire).
The Human Subjects Committee of the Harvard School of Public Health approved the specifi c study of risk factors for prostate cancer within the Health Professionals Follow-up Study.
Ascertainment and Classifi cation of Prostate Cancer Cases
For each man who reported a prostate cancer diagnosis on a follow-up questionnaire or for whom prostate cancer was mentioned on the death certifi cate, we sought medical and pathology reports pertaining to the diagnosis. Medical records and/or pathology reports were obtained for 90% of the men with prostate cancer. Study investigators who were blinded to exposure information reviewed the records to confi rm the diagnosis and to record tumor -node -metastasis (TNM) (22) stage and Gleason sum. Because the reporting of prostate cancer was found to be highly accurate, we included in the analysis the remaining 10% of cases that were based solely on self-report or on the death certificate. We excluded men who were diagnosed with stage T1a disease (n = 71) because such diagnoses are susceptible to detection bias due to differential rates of surgery for benign prostatic hyperplasia. From February 1, 1990, through January 31, 2002, 2579 cases of incident non -stage T1a prostate cancer were ascertained in 376 939 person-years of follow-up. From information in the medical records or pathology reports, we were able to determine TNM stage for 79.7% of the cases and Gleason sum for 82.1% of the cases. Cases with missing stage or grade information were included in the analysis for total prostate cancer but were excluded from the analyses for stage or grade. We categorized disease as organ confi ned (n = 1714; stage T1b to T2b and N0M0) or advanced (n = 316; regionally invasive, metastatic, or fatal [irrespective of stage at diagnosis]: stage T3b or worse, N1, M1, or death from prostate cancer) and further subdivided advanced disease into metastatic or fatal (n = 233; N1, M1, or death from prostate cancer) versus regionally invasive. Disease was considered to have been fatal if prostate cancer was recorded on the death certifi cate as the underlying cause. In the analysis by stage, we excluded men with T3a disease (i.e., minimal extraprostatic extension) to increase the specifi city of the organ-confi ned and advanced disease categorizations. We also categorized disease as lower grade (n = 1265; Gleason sum < 7) or higher grade (n = 852; Gleason sum ≥ 7). Men without information on stage were slightly older than those with information on stage (66.9 years, SD = 7.5 years, versus 62.8 years, SD = 7.9 years); after age standardization both groups of men had a similar prevalence of ever having had a screening PSA test (97.3% and 97.5%, respectively), of a history of elevated cholesterol at baseline in 1990 (35.8% and 33.6%, respectively), and of current use of cholesterol-lowering drugs at baseline in 1990 (4.5% and 4.9%, respectively).
Assessment of Statin Drug Use
In 1990 and then every 2 years, participants were asked to report their use of listed medications, including cholesterollowering drugs, during the previous 2 years. On the 2000 questionnaire only, the men were asked to report separately on their use of statin drugs and other classes of cholesterol-lowering drugs. Statins probably constituted the majority of the cholesterollowering drugs used in this cohort because they were the most commonly used type of cholesterol-lowering drug in the United States during this period ( 23 , 24 ) . Indeed, responses to the 2000 questionnaire indicated that by that year, 91% of the cholesterollowering drug used in this cohort was statins. Thus, in the analysis the use of any cholesterol-lowering drug, including the other cholesterol-lowering drugs reported in 2000, was counted as statin use. Duration of use of statin drugs was estimated by summing use across the 2-year periods encompassed by the biennial questionnaires. No information was available on brand, type, or dose of medications taken.
Statistical Analysis
We computed the directly age-standardized means and proportions for demographic and other factors by current use of statin drugs in 1994, partway through follow-up. We used Cox proportional hazards regression analysis to calculate age-adjusted and multivariable-adjusted hazard ratios (as relative risks [RRs] ) and 95% confi dence intervals (CIs) of total prostate cancer and of prostate cancer that was organ confi ned, advanced, metastatic or fatal, lower grade, or higher grade. All models were stratifi ed by age (years) and calendar time (2-year intervals). The proportional hazards assumption was tested by adding the interaction term for statin drug use and age (years) to the models; this term was not statistically signifi cant by the likelihood ratio test, confi rming the assumption.
In the main analysis we used simple updating of current use of statin drugs (i.e., we used a time-dependent variable by entering into the model whether or not a man at risk was currently using statin drugs at each failure time), where the reference group was not current users (i.e., never users or past users). Information from the prior questionnaire was carried forward when information on use was missing. We also evaluated associations with baseline (i.e., 1990) use of statins (reference group was those who did not use at baseline) and ever use of statins (reference group was never users). For updated duration of ever use, we entered into the model two indicator variables for less than 5 years and 5 or more years of use, both of which were compared with never use. To test for trend across duration of ever use, we entered into the model a continuous duration variable, the coeffi cient for which was evaluated by the Wald test.
We also carried out a multivariable analysis in which we adjusted not only for age but also for factors that have been associated with increased or decreased prostate cancer risk in previous studies of this cohort: body mass index (BMI; kg/m 2 ) at age 21 years; height (inches); updated cumulative cigarette smoking in the past decade (pack-years); cumulative fi rst-degree family history of prostate cancer; major ancestry (Scandinavian, Southern European, other white, other race); updated diagnosis of type and updated regular use of aspirin (defi ned as use at least twice per week). We did not adjust for specifi c racial ancestry because the proportion of African American men was only 0.7% and of Asian men was only 1.5%; among those men, only one and four men, respectively, were diagnosed with advanced prostate cancer.
In additional analyses, we further adjusted for factors that we hypothesized a priori might be associated with statin drug use, including updated current BMI and baseline use of medications used to treat conditions related to cardiovascular disease (e.g., beta-blockers, calcium channel blockers, diuretics, and antihypertensives, including angiotensin-converting enzyme inhibitors) and certain other ailments (e.g., oral steroids, antidepressants, and histamine type 2 receptor antagonists). In a separate set of analyses to investigate the infl uence of PSA screening on the main fi ndings of the study, we began follow-up in 1994 (the fi rst time we asked about PSA testing) and included in the model updated indicator terms for the cumulative number of 2-year periods in which a man reported having had a screening PSA test (we excluded PSA tests performed for symptoms). In another analysis, we restricted the 1994 -2002 analysis to men who had ever had a screening PSA test; men entered that analysis during the fi rst 2-year period in which they reported a screening PSA test. We ran stratifi ed models to assess whether the association between use of statin drugs and prostate cancer differed by age, use of aspirin, family history of prostate cancer, or current BMI and tested for interactions using the Wald test on a cross-product term. All statistical tests were two-sided, with P value less than .05 considered to be statistically signifi cant. All analyses were performed using SAS release 8.2 (SAS Institute, Cary, NC). Given the available number of cases and person-years of follow-up, this study had 80% power to detect as statistically signifi cant for a two-sided test with α = 0.05 a relative risk of total prostate cancer of 0.83 or lower and a relative risk of advanced disease of 0.52 or lower, comparing current statin use with nonuse.
R ESULTS
In 1990 and 1994, 4.4% and 9.3%, respectively, of the men in the cohort reported using cholesterol-lowering drugs. By 2000, 23.8% of the men used cholesterol-lowering drugs. Compared with nonusers, men who currently used statins in 1994 were older; more likely to have undergone routine physical examinations and cholesterol checks; more likely to have a history of diabetes, hypertension, and myocardial infarction; more likely to take aspirin and medications to treat cardiovascular disease risk factors; and more likely to have smoked in the past 10 years, although they ate less red meat and more fi sh ( Table 1 ) . Current users in 1994 were more likely than nonusers to report having been screened for an elevated serum PSA but were slightly less likely to report having had an elevated PSA test.
Current use of statin drugs was not associated with either total prostate cancer or organ-confi ned disease after age adjustment or after multivariable adjustment ( Table 2 ). However, compared * All values (except age) were standardized to the age distribution of the study population in 1994. Age-adjusted standard deviations for the factors with a continuous distribution were estimated from linear regression models.
† Also includes users of nonstatin cholesterol-lowering drugs (see s ubjects and Methods: Assessment of Statin Drug Use).
‡ BMI = body mass index (weight in kilograms divided by square of the height in meters).
§ Among men who reported their answer to questions on physical examination, cholesterol test, or prostate-specifi c antigen (PSA) screening test on at least one questionnaire since the start of the cohort through 2000.
|| MET-hour = metabolic equivalent of sitting at rest for an hour. Vigorous activities include running, jogging, racquet sports, swimming, and biking.
¶ Nutrient intake was adjusted for total energy intake.
with nonuse, current use was inversely associated with risk of advanced disease after adjusting for age (RR = 0.48, 95% CI = 0.29 to 0.81) and after additionally adjusting for prostate cancer risk factors (RR = 0.51, 95% CI = 0.30 to 0.86) ( Table 2 ). The age-standardized incidence rates of advanced prostate cancer were 38 and 89 per 100 000 person-years among current statin users and nonusers (i.e., never or past users), respectively. The inverse association for current use of statins was even stronger for risk of metastatic and fatal prostate cancer combined (RR = 0.39, 95% CI = 0.19 to 0.77) ( Table 2 ) and for fatal prostate cancer alone (four cases among users and 157 cases among nonusers; RR = 0.31, 95% CI = 0.11 to 0.85). We next investigated the associations for baseline use versus never use, ever use versus never use, and duration of statin use with prostate cancer. Both baseline use of statin drugs (RR = 0.41, 95% CI = 0.19 to 0.87) and ever use of statin drugs (RR = 0.54, 95% CI = 0.32 to 0.89) were inversely associated with advanced disease in comparison with never use. Risk of advanced disease decreased with increasing duration of ever use ( P trend = .003; Table 3 ). The relative risk of metastatic and fatal disease combined for fewer than 5 years of ever use compared with never use was 0.52 (95% CI = 0.27 to 1.00); no cases were observed for 5 or more years of ever use ( P trend = .002), although eight cases were expected based on the incidence rate of metastatic and fatal disease combined in the never users.
Current use of statin drugs was not associated with risk of either higher grade disease (Gleason sum ≥ 7: RR = 0.93, 95% CI = 0.75 to 1.14) or lower grade disease (Gleason sum <7:
, 95% CI = 0.55 to 1.03; P trend for duration = .21) was lower than the relative risk of lower grade disease (RR = 0.92, 95% CI = 0.71 to 1.18; P trend for duration = .81).
Because the decline over time in the incidence of advanced prostate cancer related to screening for elevated PSA may have paralleled the increase over time in the use of statins, we assessed whether PSA screening history may have confounded the associations we observed. To do so, we repeated the analyses but began follow-up in 1994, the fi rst year in which we asked the men to report on PSA screening. Beginning follow-up in 1994, the relative risks of advanced prostate cancer (all comparisons are to men who did not have a screening PSA test) were 0.85 (95% CI = 0.56 to 1.30) for having a screening PSA test during one 2-year period, 0.43 (95% CI = 0.24 to 0.78) for having a screening test in two 2-year periods, 0.26 (95% CI = 0.10 to 0.66) for having a screening test in three 2-year periods, and 0.10 (95% CI = 0.01 to 0.85) for having a screening test in four or more 2-year periods. After adjusting for this PSA screening history, the inverse association persisted between current use of statin drugs and advanced prostate cancer (beginning follow-up in 1994, n = 131 cases; RR = 0.57, 95% CI = 0.30 to 1.11) and metastatic and fatal prostate cancer (n = 84 cases; RR = 0.35, 95% CI = 0.14 to 0.92).
Restricting the analysis to only those men who reported ever having at least one PSA test and comparing current statin users with nonusers, the relative risk of total prostate cancer was 0.90 (95% CI = 0.78 to 1.08) and of advanced prostate cancer was 0.48 (95% CI = 0.24 to 0.98).
Finally, adjusting for current BMI (RR = 0.51, 95% CI = 0.30 to 0.86) or adjusting simultaneously for baseline use of other prescription medications (RR = 0.52, 95% CI = 0.30 to 0.87) did not attenuate the association between current use of statin drugs and risk of advanced disease. The association between the use of statin drugs and risk of advanced disease did not differ among strata of age, aspirin use, fi rst-degree family history of prostate cancer, or BMI (all P interaction >.25).
D ISCUSSION
In this large prospective study, statin drug use was not associated with the risk of prostate cancer overall. However, men who currently used statin drugs had about half the risk of advanced prostate cancer and less than half the risk of metastatic or fatal prostate cancer of men who did not currently use these drugs. The risk of advanced prostate cancer was lower among men with longer ever use of these drugs, compared with never use. Use of statin drugs was not associated with histologic grade. However, longer term ever users had a lower risk of high-grade disease, although the trend was not statistically signifi cant.
The question of whether there is an association between statin use and prostate cancer risk has been addressed in two recent meta-analyses of clinical trials of statins. The fi rst, which used the raw data from 14 eligible randomized clinical trials, reported a cumulative incidence of genitourinary cancers of 1.9% both in the statin and in the placebo arms; separate estimates for prostate cancer incidence were not given ( 20 ) . The other meta-analysis reported a summary odds ratio (OR) of 0.98 (95% CI = 0.83 to 1.15) for total prostate cancer incidence, based on the only three trials that provided data on prostate cancer out of 26 eligible * The reference group is men who were not currently using statin drugs. This reference group differs from that in Table 3 , in which never users are the reference group.
† Also includes users of nonstatin cholesterol-lowering drugs. ‡ RR = relative risk; CI = confi dence interval. § Relative risk adjusted for age; body mass index at age 21; height; pack-years of cigarette smoking in the previous decade; fi rst-degree family history of prostate cancer; major ancestry; diabetes mellitus; vasectomy; vigorous physical activity; use of aspirin; intakes of total energy, calcium, fructose, α -linolenic acid, tomato sauce, red meat, fi sh, and alcohol; intake of supplemental zinc; and high intake of vitamin E. trials that were reviewed as part of the meta-analysis ( 12 ) . Our fi ndings for total prostate cancer are consistent with the latter meta-analysis; we cannot determine the consistency of our fi ndings with the former meta-analysis because it did not report separate estimates for prostate cancer. However, trials included in both meta-analyses had several limitations. One was the relatively short follow-up times for cancer outcomes [mean of 5 years ( 20 ) , with only two studies performing extended follow-up of 2 years ( 25 ) and 5 years ( 26 ) after the end of the randomized part of the trial]; another was that none reported specifi cally on advanced prostate cancer, the endpoint for which we observed an inverse association.
Among the observational studies that reported on statin drug use and prostate cancer risk, two reported statistically signifi cant inverse associations between statin use and risk of total prostate cancer: Shannon et al. both observed inverse associations for total prostate cancer. Because these studies were conducted in the United States during the PSA era (i.e., 1990s and 2000s), most of these prostate cancer cases were likely to be early-stage cases. By contrast, we observed an inverse association between statin use and the risk of advanced, but not organ-confi ned, disease during the same general time period. The reasons for the differences in the fi ndings are unknown.
We evaluated the association between use of statin drugs and both total prostate cancer and advanced disease because statins infl uence many pathways that could potentially be involved in cancer development, growth, and metastasis ( 27 ) . In particular, statins inhibit 3-hydroxy-3-methylglutaryl (HMG) coenzyme A reductase, the enzyme that catalyzes the conversion of HMG coenzyme A to mevalonate, which is the rate-limiting step in cholesterol biosynthesis. The reduced availability of cholesterol for incorporation into the cell membrane could infl uence membraneassociated signaling that promotes cancer cell survival, such as Akt signaling in prostate cancer cells ( 28 -30 ) . Moreover, the reduced availability of isoprenoids derived from mevalonate for posttranslational modifi cation of proteins such as Ras and Rho could limit their localization to the cell membrane and thus their growth promotion and survival activities ( 2 , 3 ) . However, we have no data that allow us to address whether these or other biologic mechanisms account for the inverse association that we observed between statin use and the risk of advanced prostate cancer.
Several issues related to the design and analysis of this study may infl uence the inferences that may be drawn from it and thus warrant discussion. The fi rst issue is how we classifi ed statin use. Statins were fi rst introduced to the US market in 1987, and soon afterward their use surpassed that of other cholesterol-lowering drugs ( 23 , 24 ) . Based on these national use patterns and on data from this cohort on types of cholesterol-lowering drug used as reported in the 2000 questionnaire, we considered any use of * Also includes users of nonstatin cholesterol-lowering drugs. † The reference group is men who never used statin drugs. This reference group differs from that in Table 2 , in which men who were not currently using statin drugs are the reference group.
‡ From a Wald test of the β coeffi cient for duration of use. § RR = relative risk; CI = confi dence interval. || Relative risk adjusted for age; body mass index at age 21; height; pack-years of cigarette smoking in the previous decade; fi rst-degree family history of prostate cancer; major ancestry; diabetes mellitus; vasectomy; vigorous physical activity; use of aspirin; intakes of total energy, calcium, fructose, α -linolenic acid, tomato sauce, red meat, fi sh, and alcohol; intake of supplemental zinc; and high intake of vitamin E.
¶ The expected number of cases based on the age-and time period -specifi c incidence rates in the never users is 8.0.
cholesterol-lowering drugs to represent statin use in the analysis reported here. In any event, misclassifi cation of other cholesterol-lowering drugs as statins or misclassifi cation of use due to inaccurate self-reporting of the use of these drugs should not be differential with respect to diagnosis of prostate cancer because the analysis was prospective. The effect of this type of error would lead to a relative risk estimate closer to the no-association value of 1.0. Thus, misclassifi cation of statin drugs is highly unlikely to account for the strong inverse association that we observed for advanced prostate cancer. A second issue relates to the conduct of the study in the PSA era. Since the advent of widespread PSA screening, advanced prostate cancer is less often diagnosed, but when it is, it is more often diagnosed in men who have not undergone PSA screening or who have been screened infrequently. In this cohort, statin users were more likely than nonusers to have had one or more screening PSA tests and men with multiple screening PSA tests were more likely than men with fewer tests to be diagnosed with organ-confi ned prostate cancer but less likely to be diagnosed with advanced disease. Thus, we took steps to assess whether a different extent of use of PSA screening between statin users and nonusers might account for our fi ndings by conducting subanalyses in which we began follow-up in 1994, which was fully in the PSA era. We used two approaches to consider PSA screening history in these subanalyses: adjusting for updated cumulative number of periods in which a man had a screening PSA test and restricting the analysis to person-time at risk during which a screening PSA test was performed. With both approaches, the inverse association between statin use and risk of advanced and metastatic and fatal prostate cancers remained. Nevertheless, although PSA screening did not appear to account for our fi ndings, we cannot rule out bias due to subtle differences in patterns of PSA screening between statin users and nonusers.
A third issue is the nonresponse to the baseline questions on medications use; 22% of the otherwise eligible men were excluded from the analysis because they had not provided information on medication use at baseline. The analysis we conducted was prospective, and thus, the likelihood of selection bias as a result of differential nonresponse was small. Nevertheless, we explored this possibility. Men who did and did not provide information on medication use at the start of follow-up in 1990 did not differ substantially on age, PSA screening history, history of elevated cholesterol, or the prevalence of statin drug use in 2000. Further evidence that the fi ndings of this study were not due to selection bias comes from the result of an additional analysis (not shown) in which we started follow-up in 1994 and counted as statin users men who indicated such use in either 1992 or 1994; 58% of the men excluded from the analysis for lack of information on medication use in 1990 did provide information on medication use subsequently on the 1992 or 1994 questionnaires. In that analysis, the multivariable relative risk of advanced disease was 0.39 (95% CI = 0.18 to 0.84), similar to what was observed in the main analysis.
The fourth issue is the possibility of confounding or differential detection of prostate cancer by use of medical care. However, because of the large study size and the extensive information collected on each cohort member, we were able to control for a number of known and suspected risk factors for prostate cancer that may co-occur with use of statins, such as dietary and lifestyle factors, including the use of aspirin. The inverse association between statins and advanced prostate cancer remained even after multivariable adjustment. We also adjusted for use of prescription medications, including antihypertensive drugs, such as angiotensin-converting enzyme inhibitors, to assess confounding and differential detection. The inverse association between statin use and risk of advanced prostate cancer remained, indicating a lack of confounding by use of other medications. Furthermore, there was no consistent pattern of association between the use of prescription medications and risk of prostate cancer (data not shown). We would have expected that many prescription drugs would have been inversely associated with advanced prostate cancer if going to the doctor increased both the likelihood of receiving a prescription and the likelihood of having a screening PSA test.
The fi fth issue is the small sample size in a few of the subgroup analyses. The overall study had a large sample size, which allowed us to investigate the association of current statin use, not only with total prostate cancer but also with advanced disease. The clinically important prostate cancer endpoint that should be the target for prevention is advanced disease, which is the most likely stage to lead to death. In the analysis of duration of ever use, the number of cases of total prostate cancer with longer term ( ≥ 5 years) ever use remained large, at 126. For advanced and metastatic plus fatal disease, the numbers of cases with longer term ever use were three and zero, respectively. However, the expected number of metastatic or fatal cases for 5 or more years of use was eight, which was calculated using the more than 18 500 person-years at risk in those with 5 or more years of use and the observed age-and period-specifi c incidence rates in the never users. Thus, the lack of men with metastatic or fatal prostate cancer among the longer term users was not due merely to a small number of person-years at risk contributed by those men but instead can be explained by a defi cit of these cases (zero instead of an expected eight cases) during their time at risk when compared with the never users.
In summary, our prospective results do not support an association between the use of statin drugs and the risk of prostate cancer overall, but they do suggest that statin use is associated with a reduced risk of clinically important advanced prostate cancer in a population that reported a high prevalence of routine PSA screening. However, it is premature to recommend the use of statins for the prevention of advanced prostate cancer. Further work is needed to address the role of PSA screening as a possible explanation for these fi ndings and to identify the biologic mechanisms that may underlie the inverse association, if this association is indeed causal.
